Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of Enoxaparin Dosing to Achieve Anti-Factor Xa Thromboprophylaxis Levels in Super Morbidly Obese Patients Undergoing Bariatric Surgery
TCTR20221227001Phase 3Unknown
- Sponsor
- Chulalongkorn University
- Start
- Sep 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of enoxaparin in venous thromboembolism (VTE), sponsored by Chulalongkorn University. Status: unknown.
02
Drugs
enoxaparin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on TCTR20221227001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20221227001.